Sunlenca
Total Payments
$8.7M
Transactions
1,692
Doctors
493
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.8M | 241 | 57 |
| 2023 | $1.1M | 1,085 | 450 |
| 2022 | $3,660 | 1 | 0 |
| 2021 | $1.1M | 28 | 0 |
| 2020 | $3.5M | 185 | 0 |
| 2019 | $1.3M | 152 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.3M | 841 | 95.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $293,888 | 137 | 3.4% |
| Food and Beverage | $54,907 | 587 | 0.6% |
| Travel and Lodging | $41,859 | 116 | 0.5% |
| Consulting Fee | $16,970 | 11 | 0.2% |
Payments by Type
Research
$8.3M
841 transactions
General
$407,623
851 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Double-Blinded, Randomized, Placebo- and Positive-Controlled, Parallel Study With Nested Crossover Design to Evaluate the Effect of Lenacapavir (LEN) on the QT/QTc Interval in Healthy Participants | Gilead Sciences, Inc. | $3.1M | 0 |
| A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects | Gilead Sciences, Inc. | $1.4M | 0 |
| GS-US-200-5710 - A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneous and Intramuscular Lenacapavir | Gilead Sciences, Inc. | $836,483 | 0 |
| A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-6207 in Subjects with Normal and Impaired Hepatic Function | Gilead Sciences, Inc. | $702,667 | 0 |
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $595,892 | 0 |
| A Phase 1 Open-Label, Parallel-Design, Single-Dose Study to Evaluate the Pharmacokinetics of GS-6207 in Participants with Normal Renal Function and Severe Renal Impairment | Gilead Sciences, Inc. | $591,738 | 0 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $399,700 | 0 |
| A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of GS-6207 | Gilead Sciences, Inc. | $262,995 | 0 |
| A Phase 1 Study to Evaluate the Effect of Subcutaneous (SC) Injection Site on Pharmacokinetics (PK) of Lenacapavir (LEN) | Gilead Sciences, Inc. | $229,868 | 0 |
| Perspectives on Innovative HIV Treatment among Treatment Experienced Black Women Living with HIV Infection (in New York State) | Gilead Sciences, Inc. | $101,000 | 0 |
| Acceptability of Long-Acting Injectable Lenacapavir Among Heavily Treatment Experienced Individuals with HIV within the CAPELLA Clinical Trial and the Lenacapavir IPU Program (US Only): Qualitative Insights to Support Real-World Implementation. | Gilead Sciences, Inc. | $64,772 | 0 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Metabolism and Excretion of IV GS6207 in Healthy Subjects | Gilead Sciences, Inc. | $3,660 | 0 |
Top Doctors Receiving Payments for Sunlenca
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sacramento, CA | $8.3M | 844 |
| , M.D | Internal Medicine | Oakland, CA | $25,043 | 35 |
| , MD | Infectious Disease | Newark, NJ | $19,943 | 16 |
| , MD | Infectious Disease | Chattanooga, TN | $15,980 | 18 |
| , M.D | Infectious Disease | Boston, MA | $14,534 | 11 |
| , M.D | Gastroenterology | Los Angeles, CA | $12,762 | 10 |
| , MD | Infectious Disease | Baltimore, MD | $12,710 | 15 |
| , D.O | Internal Medicine | Tulsa, OK | $12,112 | 16 |
| , MD | Infectious Disease | Chicago, IL | $10,365 | 9 |
| , D.O | Internal Medicine | Lansing, MI | $10,180 | 12 |
| , MD | Internal Medicine | Plantation, FL | $8,693 | 13 |
| , M.D | Infectious Disease | Decatur, GA | $8,265 | 9 |
| , MD | Infectious Disease | Saint Louis, MO | $8,233 | 10 |
| , MD | Infectious Disease | Altamonte Springs, FL | $8,093 | 7 |
| , M.D | Infectious Disease | Los Angeles, CA | $7,707 | 6 |
| , MD | Infectious Disease | Philadelphia, PA | $7,647 | 7 |
| , M.D | Infectious Disease | Cape Coral, FL | $7,232 | 6 |
| , MD | Infectious Disease | Washington, DC | $6,864 | 7 |
| , MD | Internal Medicine | Catskill, NY | $6,632 | 5 |
| , M.D | Infectious Disease | Louisville, KY | $6,030 | 6 |
| , MD | Adult Medicine | Phoenix, AZ | $6,017 | 8 |
| Philip Palmieri | Infectious Disease | Albany, NY | $5,794 | 7 |
| Edward Liu | — | Neptune, NJ | $5,638 | 6 |
| , PA | Internal Medicine | Daytona Beach, FL | $5,578 | 9 |
| , M.D | Family Medicine | Austin, TX | $5,458 | 5 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $8.7M
Product Information
- Type Drug
- Total Payments $8.7M
- Total Doctors 493
- Transactions 1,692
About Sunlenca
Sunlenca is a drug associated with $8.7M in payments to 493 healthcare providers, recorded across 1,692 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences, Inc..
Payment data is available from 2019 to 2024. In 2024, $1.8M was paid across 241 transactions to 57 doctors.
The most common payment nature for Sunlenca is "Unspecified" ($8.3M, 95.3% of total).
Sunlenca is associated with 12 research studies, including "A Phase 1, Double-Blinded, Randomized, Placebo- and Positive-Controlled, Parallel Study With Nested Crossover Design to Evaluate the Effect of Lenacapavir (LEN) on the QT/QTc Interval in Healthy Participants" ($3.1M).